Late diagnoses of Dravet syndrome: How many individuals are we missing?

Katri Silvennoinen¹², Clinda Puvirajasinghe³, Kirsty Hudgell⁴, Meneka K. Sidhu¹², Helena Martins Custodio¹², Genomics England Research Consortium⁵*, Wendy D. Jones¹³, Simona Balestrini¹²⁶, Sanjay M. Sisodiya¹²

*Genomics England Research Consortium contributors are listed in Appendix I

¹ Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK
² Chalfont Centre for Epilepsy, Chalfont St Peter, UK
³ North East Thames Regional Genetics Service, Great Ormond Street Hospital, London, UK
⁴ St. Elizabeth’s Centre, Much Hadham, Herts, UK
⁵ Genomics England, London, UK
⁶ University of Florence, Children’s Hospital A. Meyer, Florence, Italy

Corresponding author: Sanjay M Sisodiya, Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, Box 29, Queen Square, London WC1N 3BG, United Kingdom. Tel: +44 (0) 2034488612; Fax: +44 (0) 20 3448 8615; Email: s.sisodiya@ucl.ac.uk

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/EPI4.12525

This article is protected by copyright. All rights reserved
Abstract

We report new genetic diagnoses of Dravet syndrome in a group of adults with complex epilepsy of unknown cause, under follow up at a tertiary epilepsy centre. Individuals with epilepsy and other features of unknown cause from our unit underwent whole genome sequencing through the 100,000 Genomes Project. Virtual gene panels were applied to frequency-filtered variants based on phenotype summary. Of 1078 individuals recruited, 8 (0.74%) were identified to have a pathogenic or likely pathogenic variant in SCN1A. Variant types were: nonsense (stopgain) in five (62.5%) and missense in three (37.5%). Detailed review of childhood history confirmed a phenotype compatible with Dravet syndrome. Median age at genetic diagnosis was 44.5 years (range 28-52 years). Tonic-clonic seizures were ongoing in all despite polytherapy including valproate. All had a history of fever sensitivity and myoclonic seizures, which were ongoing in two (25%) and three (37.5%) individuals, respectively. Salient features of Dravet syndrome may be less apparent in adulthood, making clinical diagnosis difficult. Regardless of age, benefits of a genetic diagnosis include access to syndrome-specific treatment options, avoidance of harmful drugs, and monitoring for common complications.

Keywords: epilepsy; seizures; genetics; whole genome sequencing

Introduction

This article is protected by copyright. All rights reserved
Dravet syndrome (DS) is one of the commonest, best-characterised, severe, monogenic epilepsies. Individuals with DS typically present within the first year of life with convulsive seizures, often precipitated by pyrexia.\textsuperscript{1} Seizures become recurrent and later often include myoclonic and atypical absence seizures. Focal-onset seizures of various semiologies are also common.\textsuperscript{1} Developmental delay becomes evident typically from the second year onwards.\textsuperscript{1} The majority of individuals have moderate to severe intellectual disability by adulthood.\textsuperscript{2,3}

DS is typically caused by loss of function variants in the gene \textit{SCN1A}, particularly affecting inhibitory interneurons.\textsuperscript{4} The majority of pathogenic variants arise \textit{de novo}.\textsuperscript{5} DS is now widely recognised by paediatricians and neurologists, and \textit{SCN1A} molecular testing is available in many countries. However, older patients especially may remain undiagnosed;\textsuperscript{6} the prevalence in age epochs across adulthood is unknown. We describe a series of individuals diagnosed with DS in adulthood based on whole genome sequencing.

\textbf{Methods}

This study was approved by the Camden & Kings Cross Research Ethics Committee (reference 11/LO/2016). The participants did not have capacity to provide informed consent; written assent for participation was obtained from a personal consultee for each individual following the approved protocol.

Participants fulfilling criteria for the ‘epilepsy plus other features’ category (epilepsy with structural abnormality of the brain or other organs, cognitive impairment, autism, or consanguinity)\textsuperscript{7}, with no known genetic diagnosis, were recruited to the UK 100,000 Genomes Project and underwent whole-genome sequencing.\textsuperscript{8} Reads were aligned to build GRCh38 of the human genome. Virtual gene panels\textsuperscript{9} were chosen based on the phenotype summary entered at time of recruitment and applied to frequency-filtered variants (Table S1). Results were reviewed in a multidisciplinary meeting with epileptology, clinical and molecular genetics input, and classified according to the Association for Clinical Genomic Science guidelines.\textsuperscript{10} Further clinical data were obtained from medical records and epilepsy genomics clinic reviews.

Prior to this analysis, one individual was identified through screening within the Genomics England Research Environment for stopgain variants in the \textit{SCN1A} gene region (chr2:165989160-166128013).\textsuperscript{6} The finding was confirmed in the present analysis.
Descriptive statistics were calculated using Microsoft Excel version 16.38. Due to small sample size, central tendency was expressed using medians.

**Results**

A total of 1078 individuals were recruited from our unit. Eight individuals (six females and two male) were found to have heterozygous pathogenic variants in *SCN1A* (Table 1). The median age at genetic diagnosis was 44.5 years (range 28-52; Table 2). In one of the individuals (12.5%), a diagnosis of Dravet syndrome had been previously suspected by the treating physician. In three others (37.5%), electronic patient records were, in retrospect, sufficient for suspecting the diagnosis. In the remaining four (50%), sufficient details to make a clinical diagnosis of DS were not present in available electronic patient records, but subsequent review of historical (paper) notes highlighted that their phenotype was indeed compatible with DS (Table 2). All variants were absent from The Genome Aggregation Database (gnomAD). Four of the variants had been previously reported in individuals with DS, with additional functional evidence for two of these variants (Table S2). Due to the age of our patients and inability to obtain parental samples in many cases, parental testing was possible only in one individual, with confirmation of *de novo* status of the *SCN1A* variant.

None of these individuals had any additional filtered variants felt to be contributing to their phenotype.

The median age of seizure onset was 6 months (2.5-10). In seven (87.5%), the first seizure occurred in the context of pyrexia. Two individuals had received a vaccination in the preceding 24 hours.

Median age of onset of developmental delay was 2.5 years (range 1.25-4). All patients had a history of bilateral tonic-clonic seizures (TCS) and myoclonic jerks. Six individuals had a history of focal onset non-motor seizures with impaired awareness (FIAS); EEGs were not available to confirm atypical absences. Other seizure types ever included focal-onset motor seizures (two individuals), unclassified drops/episodes of head nodding (two individuals), and tonic seizures (one individual). All patients had ongoing TCS. Myoclonic seizures were ongoing in three. FIAS continued in one. One patient had unclassified episodes of eyelid fluttering. Fever or intercurrent illness was elicited as an ongoing seizure precipitant in two.
Seven (87.5%) patients had data on previous and current motor and language skills. All seven had deterioration in mobility compared to their best attained level; however, all continued to be able to walk for at least short distances. Language skills ranged from no verbal communication to ability to have a basic conversation using sentences. Four of seven (57.1%) had deterioration in language skills compared to their best level.

All patients were taking valproate at current presentation. The median number of current antiseizure treatments (including ketogenic diet) was 3 (range 2-4). The median number of previously tried antiseizure treatments (excluding rescue medications) was 11 (range 5-15). All patients had a history of sodium channel blocker (SCB) treatment. Five individuals (62.5%) had documented deterioration in seizure frequency and/or severity whilst on lamotrigine or carbamazepine.

**Discussion**

DS is among the most common monogenic epileptic encephalopathies, with an estimated population-based incidence of about 1/15500 live births. Although some individuals succumb in childhood, recent estimates suggest over 80% will require care in adult services. We conclude, therefore, that a number of adult patients are currently undiagnosed and have unmet health needs. Our experience highlights the need to consider a genetic diagnosis among older individuals with treatment-resistant epilepsy.

DS is now, and has been historically, typically diagnosed in childhood; therefore, the commonly appreciated key clinical features reflect the childhood presentation. It is recognised that TCS persist in adulthood in the majority of individuals with DS, while seizure types characteristic in childhood, including myoclonic seizures and atypical absence seizures, continue to occur only in a minority. In our series also, TCS were ongoing in all, while half of patients had no other definite seizures. In previous series of adult with DS, gait impairment of variable severity, including crouch gait, and significant language impairment were reported in the majority; swallowing difficulties are also a recognised late feature in some. In keeping with the previous literature, all our patients had at least one of these three features. While non-specific, these features might alert to a possible diagnosis of DS in adults with refractory epilepsy.

In our group of adults with epilepsy and other features, a new genetic diagnosis of DS could be made in 0.74%, a relatively high proportion for a single syndrome. In our view, all adults with
refractory epilepsy and intellectual disability of unknown cause should be suspected of having a possible genetic cause, including DS, and be offered genetic testing. In those with seizure onset before age 1 year, fever sensitivity and history of myoclonic seizures, testing for SCN1A variants might be undertaken directly. Whilst reviewing the childhood notes of all adults with refractory epilepsy for features of syndromic diagnoses would seem prudent, in reality, such notes may not be available and such review would be a sizeable task in large busy clinics. Panels incorporating a number of genes associated with epilepsy, such as those used in this study (Table S1), provide a cost-effective way to screen for variants in multiple genes, including other genes associated with a Dravet-like phenotype.

Among the widely available antiseizure medications (ASMs), established treatments for DS include valproate, clobazam and topiramate. Despite lack of a syndromic diagnosis, all our patients had arrived to polytherapy incorporating valproate and half also took regular clobazam. Despite these treatments, all continue to have TCS. Emerging or licensed treatments for DS include stiripentol, cannabidiol and fenfluramine. Establishing a diagnosis of DS may help fulfil local criteria necessary for access to these drugs, or future treatments on a research basis or through early access programmes.

One of the diagnostic clues for DS is exacerbation of seizures by SCBs, and avoiding these presents one of the earliest genetics-driven treatment approaches. All of our patients had a history of SCB use; in five, this was associated with clearly-documented exacerbation of seizures. One of these patients remains on oxcarbazepine. Withdrawal of SCBs has been associated with benefit also in older individuals, and will be considered in this patient.

A multidisciplinary approach is helpful to address the common complications of DS that include dysphagia and progressive gait problems. Making the diagnosis allows for appropriate monitoring and therapy input as necessary. People with DS are at high risk of sudden unexpected death in epilepsy (SUDEP), providing further motivation to optimise seizure control. Arriving at a genetic diagnosis may provide an end to a decades-long diagnostic odyssey for families. The diagnosis may also have implications in terms of genetic counselling for the wider family, as some causal variants may be inherited.

Estimation of rare disease prevalence is a step forward in promoting disease-specific treatments, as prevalence influences funding priorities and is helpful for planning of clinical trials. Estimation of the prevalence of DS in adulthood currently relies on incidence at birth. We suggest our
A cross-sectional study highlights the need for widespread access to genetic testing among adults with treatment-resistant epilepsies, as there are clearly undiagnosed adults.

Appendix I

Genomics England Research Consortium contributors: J. C. Ambrose5, P. Arumugam5, E. L. Baple, M. Bleda5, F. Boardman-Pretty5, J. M. Boissiere5, C. R. Boustred5, M. J. Caulfield5, G.C. Chan5, C. E. H. Craig5, L. C. Daugherty5, A. de Burca5, A. Devereau5, G. Elgar5, R. E. Foulger5, T. Fowler5, P. Furió-Tari5, J. M. Hackett5, D. Halai5, A. Hamblin5, S. Henderson5, J. E. Holman5, T. J. P. Hubbard5, K. Ibáñez5, R. Jackson5, L.J. Jones5, D. Kasperaviciute5, M. Kayikci5, L. Lahnstein5, K. Lawson5, S. E. A. Leigh5, I. U. S. Leong5, F. J. Lopez5, F. Maleady-Crowe5, J. Mason5, E. M. McDonagh5, L. Moutsianas5, M. Mueller5, N. Murugaesu5, A. C. Need5, C. A. Odhams5, C. Patch5, D. Perez-Gil5, D. Polychronopoulos5, J. Pullinger5, T. Rahim5, A. Rendon5, P. Riesgo-Ferreiro5, T. Rogers5, M. Ryten5, K. Savage5, K. Sawant5, R. H. Scott5, A. Siddiq5, A. Sieghart5, D. Smedley5, K. R. Smith5, A. Sosinsky5, W. Spooner5, H. E. Stevens5, A. Stuckey5, R. Sultana5, E. R. A. Thomas5, S. R. Thompson5, A. Tucci5, E. Walsh5, S. A. Watters5, M. J. Welland5, E. Williams5, K. Witkowska5,

Genomics England, London, UK

William Harvey Research Institute, Queen Mary University of London, London, EC1M 6BQ, UK.

Acknowledgements

This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. Part of this work was undertaken at University College London Hospitals, which received a proportion of funding from the NIHR Biomedical Research Centres funding scheme who also support MKS. KS was supported by a Wellcome Trust.
Strategic Award (WT104033AIA). SB was supported by the Muir Maxwell Trust and Epilepsy Society.

Disclosure of Conflicts of Interest
None of the authors has any conflict of interest to disclose.

Ethical Publication Statement
We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Data Accessibility Statement
Access to genetics data of the 100,000 Genomes Project may be obtained via membership of the Genomics England Clinical Interpretation Partnership (GeCIP; https://www.genomicsengland.co.uk/about-gecip/joining-research-community/).

References
1. Dravet C. The core Dravet syndrome phenotype. Epilepsia 2011;52:3–9.
2. Darra F, Battaglia D, Dravet C, Patrini M, Offredi F, Chieffo D, et al. Dravet syndrome: Early electroclinical findings and long-term outcome in adolescents and adults. Epilepsia 2019;60:S49–58.
3. Catarino CB, Liu JYW, Liagkouras I, Gibbons VS, Labrum RW, Ellis R, et al. Dravet syndrome as epileptic encephalopathy: Evidence from long-term course and neuropathology. Brain 2011;134:2982–3010.
4. Catterall WA. Dravet syndrome: a sodium channel interneuronopathy. Curr Opin Physiol 2018;2:42–50.
5. Marini C, Scheffer IE, Nabbout R, Suls A, De Jonghe P, Zara F, et al. The genetics of Dravet syndrome. Epilepsia 2011;52:24–9.
6. Silvennoinen K, Martins Custodio H, Balestrini S, Rugg-Gunn F, England Research Consortium G, Sisodiya SM. Complex epilepsy: it’s all in the history. Pract Neurol 2021;21:153-156.
7. Scott R, Devereau A, Thomas E. Rare Disease Conditions Eligibility Criteria. Version 1.9.0. Genomics Engl. 2017;(1):287. Available from https://www.genomicsengland.co.uk/wp-content/uploads/2018/06/Rare-Disease-Eligibility-Criteria-v1.9.0-PAR-GUI-058_approved-version-1.pdf

8. Turnbull C, Scott RH, Thomas E, Jones L, Murugaesu N, Pretty FB, et al. The 100 000 Genomes Project: Bringing whole genome sequencing to the NHS. BMJ 2018;361:1–7.

9. Martin AR, Williams E, Foulger RE, Leigh S, Daugherty LC, Niblock O, et al. PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels. Nature Genetics 2019;51:1560–1565.

10. Ellard S, Baple EL, Callaway A, Berry I, Forrester N, Turnbull C, et al. ACGS best practice guidelines for variant classification in rare disease 2020. Association for Clinical Genomics Science (ACGS). Published 04/02/2020. Available from: https://www.acgs.uk.com/media/11631/uk-practice-guidelines-for-variant-classification-v4-01-2020.pdf

11. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 2020;581:434–43.

12. Symonds JD, Zuberi SM, Stewart K, McLellan A, O’Regan M, MacLeod S, et al. Incidence and phenotypes of childhood-onset genetic epilepsies: A prospective population-based national cohort. Brain 2019;142:2303–18.

13. Lewis-Smith D, Ellis CA, Helbig I, Thomas RH. Early-onset genetic epilepsies reaching adult clinics. Brain 2020;143:1–6.

14. Takayama R, Fujiwara T, Shigematsu H, Imai K, Takahashi Y, Yamakawa K, et al. Long-term course of Dravet syndrome: A study from an epilepsy center in Japan. Epilepsia 2014;55:528–38.

15. Wheless JW, Fulton SP, Mudigoudar BD. Dravet Syndrome: A Review of Current Management. Pediatr Neurol 2020;107:28–40.

16. Nabbout R. Impact of predictive, preventive and precision medicine strategies in epilepsy. Nat Rev Neurol 2020;16:674–688.

This article is protected by copyright. All rights reserved
17. Shmuely S, Sisodiya SM, Gunning WB, Sander JW, Thijs RD. Mortality in Dravet syndrome: A review. Epilepsy Behav 2016;64:69–74.

Supporting information

Table S1: Genomics England PanelApp (1) virtual gene panels applied in the genome interpretation pipeline for each participant.

Table S2: Details of previous reports of the SCN1A variants identified in people in this study, where applicable.
### Tables

Table 1. *SCN1A* variant details and current presentation.

| ID | *SCN1A* variant (all heterozygous) | Variant type; ACGS classification[^10] | Age | Clinical diagnoses prior to genetic testing | Current seizures | Current ASMs | Current mobility | Current language skills | Comorbidities |
|----|-----------------------------------|--------------------------------------|-----|--------------------------------------------|------------------|--------------|----------------|-------------------------|---------------|
| 1  | NM_001165963.1: c.1489del:p.Arg497GlufsTer47 | Nonsense Class 5 (PM2; PVS1) | 46  | 1. Cryptogenic epilepsy  
2. Learning disability  
3. Spastic quadriplegia | TCS (2/y), MJ | OXC 1350, LEV 2000, VPA 1500, CLB 10 | Crouch gait, wheelchair for longer distances | | Scoliosis  
Possible swallowing problems |
| 2  | NM_001165963.1: c.1754dup:p.Ser586IlefsTer2 | Nonsense Class 5 (PM2; PVS1; PM6_sup) | 28  | 1. Epilepsy with generalised tonic-clonic seizures and episodes with eyelid fluttering.  
2. Severe developmental delay of unknown aetiology. | TCS (51/y); ?eyelid fluttering | PER 4, VPA 1000, LEV 250, CLB 20 | Walks with crouch gait | | Non-verbal  
History of aspiration pneumonia |
| 3  | NM_001165963.1: c.3796G>T: p.Glu1266Ter | Nonsense Class 5 (PM2, PVS1;) | 52  | 1. Generalised tonic-clonic seizures  
2. Spastic quadraparesis  
3. Severe learning | TCS (7/y) | VPA 1000, CLZ 2, LEV 3000, LCM 350 | Able to take walk short distances indoors | | Non-verbal  
Nil |
| # | NM_001165963.1:  
c.4003G>A:  
p.Val1335Met  
Prev. reported* | Missense  
Class 4  
(PM2; PP2; PP3;  
PS4_mod) | 51 | 1. Pharmacoresistant epilepsy.  
2. Severe learning disability | TCS (12/y),  
MJ  
(preceding TCS) | VPA 1400, CLB 25, Primidone 625 | Able to walk but unsteady  
Single words  
Nil |
|---|---|---|---|---|---|---|---|
| 5 | NM_001165963.1:  
c.1647C>A:  
p.Tyr549Ter  
Prev. reported* | Nonsense  
Class 5  
(PM2; PVS1) | 34 | 1. Pharmacoresistant focal epilepsy  
2. Learning disability | TCS (72/y) | LEV 2000, VPA 1200, LCM 300 | Able to walk short distances,  
back hunched  
Words and some phrases  
Nil |
| 6 | NM_006920.4:  
c.664C>T:  
p.Arg222Ter  
Prev. reported* | Nonsense  
Class 5  
(PM2; PVS1;  
PS4_mod; PM6) | 43 | 1. Refractory partial epilepsy  
2. Possible history of Landau-Kleffner syndrome  
3. Severe learning disability | TCS (1-2/y)  
FIAS (30/y) | CLB 20, VPA 1100, ZON 100 | Able to walk  
Vocabulary 30 words,  
some phrases  
Scoliosis. Impaired swallowing,  
hypothyroidism |
| 7 | NM_001165963.1:  
c.548T>C:  
p.Phe183Ser | Missense  
Class 4 | 47 | 1. Pharmacoresistant epilepsy  
2. Possible Dravet | TCS 5/y | TPM 500, VPA 800 | Able to walk but unsteady  
Non-verbal  
Impaired swallowing - modified diet |
|     | NM_001165963.1:c.1178G>A: p. Arg393His | Syndrome                                         | Class | Medicine                          | Description                                      | Details                                                                 |
|-----|-------------------------------------|-------------------------------------------------|-------|-----------------------------------|-------------------------------------------------|------------------------------------------------------------------------|
| 8   | Prev. reported*                     | 3. Learning disability                          | 42    | TCS 4/y, MJ                       | Gait ataxic and slow                             | Speaks in sentences, able to have basic conversation                  |
|     |                                     | 1. Pharmacoresistant focal epilepsy             |       | ZON 400, VPA 1600, LCM 400       | Scoliosis                                        |                                                                        |
|     |                                     | 2. Severe learning disabilities                 |       |                                   |                                                  |                                                                        |

Abbreviations: ACGS – Association for Clinical Genomic Science; CBZ – carbamazepine; CLB – clobazam; TCS – tonic-clonic seizures; LCM – lacosamide; LEV – levetiracetam; LTG – lamotrigine; FIAS – focal onset non-motor seizures with impaired awareness; MJ – myoclonic jerks; OXC – oxcarbazepine; PER – perampanel; VAP – valproate; ZON – zonisamide

*details of previous reports may be found in Table S2
Table 2. History of epilepsy and development

| ID | Gender | Age and type of seizure onset | Age at onset of developmental delay | Motor functions/mobility at best | Language abilities at best | Overall cognitive abilities at best as assessed by psychology | Behavioural/neuropsychiatric history | First record of abnormal EEG | Seizure types ever | No of previous ASM/therapies | Response to SCBs |
|----|--------|------------------------------|-----------------------------------|---------------------------------|---------------------------|---------------------------------------------------------------|-----------------------------------|------------------------|-------------------|-----------------------|----------------|-----------------|
| 1  | M      | 2.5mo; febrile focal motor   | 15mo                              | Age 4: “Loved climbing and escaping”; walked independently without problems | Single words/2-word phrases; 1-2-yo level (age 29) | 2-3 yo level (age 29) | Hyperactive, occasional aggressive behaviour, difficulties getting out of car. Low mood as adult | Age 15mo (details unknown) | TCS, MJ, FIAS, “head nodding and arms outstretched” | 11 | N/A | LTG - deterioration |
| 2  | F      | 6mo; febrile                 | 3y                                | Able to run                     | Single words              | N/A                | N/A                                             | Age 12 y - | TCS, MJ, FIAS | 8        | N/A |
|   |   |   |   |   |   |
|---|---|---|---|---|---|
|   |   |   |   |   |   |
| TCS | Possibly episodes of eye deviation from age 4mo |   |   |   |
|   |   |   |   |   |   |
| 3 | M | 9mo; febrile 4y | Able to run, cycle, play ball games (around age 8-10) | Vocabulary 70 words; short phrases (age 21y) | N/A | Hyperactive; can spend hours on some activities | Age 10y - encephalopathic eyelid fluttering with cessation of activity |
|   |   |   |   |   |   |   |   |
| 4 | F | 6mo; febrile 6h after vaccination 2-3y | Age 17 - enjoys indoor hockey, good at throwing and catching balls | Short 2-3 word phrases, many single word utterances – at level of 2.7 yo (age 18y) | N/A | Compulsive, hyperactive by age 5 “Can be very obsessive when it comes to use of free time” | Age 1.5y - encephalopathic |
|   |   |   |   |   |   |   |   |
| 5 | F | 10mo; non-3y | Able to run | Words and | N/A | N/A | Age 9.5y – |
|   |   |   |   |   |   |   |   |
|   |   |   |   |   |   |   |   |
|   |   |   |   |   |   |   |   |

This article is protected by copyright. All rights reserved
| # | Gender | Age | Onset | Symptoms | Seizure Type | EEG | MRI | Other Observations |
|---|---|---|---|---|---|---|---|---|
| 6 | F | 2 | 4mo; febrile TCS | Poor balance but able to run | Words and some phrases | TCS, MJ, FIAS | N/A | preceded TCS |
| 7 | F | 6mo; febrile; within 24h of vaccination | 2y | N/A | N/A | N/A | N/A | Manic episode as adult |
| 8 | F | 2 | 9mo; febrile hemiclonic | Able to ride a bike, hop and jump, climb (age 6.5), also roller-skate | Speaks in sentences, able to have basic conversation | TCS, MJ, FIAS, tonic, focal motor onset | N/A | Deterioration on LTG |

Abbreviations: CBZ – carbamazepine; FIAS – focal onset non-motor seizures with impaired awareness; TCS - tonic-clonic seizures; LTG – lamotrigine; MJ – myoclonic jerks; SCBs – sodium channel blocker.